Full Thickness Macular Hole; Should it be Handled Subacutely?
Full Thickness Macular Hole
About this trial
This is an interventional treatment trial for Full Thickness Macular Hole focused on measuring Phako, Vitrectomy, Phako-vitrectomy, FTMH
Eligibility Criteria
Inclusion Criteria: Idiopathic full thickness macular hole Duration of symptoms of <30 days for Group 1 and 2 Duration of symptoms of 3-12 months for Group 3 FTMH size <400µm >18 years Able to give informed consent Compliance for postoperative positioning Exclusion Criteria: High myopia (≤-3) Traumatic macular hole Prior ocular surgery, including cataract surgery Other ocular diseases compromising the visual acuity (i.e., AMD, diabetic retinopathy, previous vein occlusion) Posterior vitreous detachment (Weiss ring)
Sites / Locations
- Rigshospitalet, DenmarkRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
Combined Phako-Vitrectomy for FTMH
Sequential phako and vitrectomy for FTMH
Longstanding FTMH
Study 1: Patient randomized to this arm will receive a combined phako-vitrectomy within two weeks from referall day.
Study 1: Patients randomized to this arm will receive a standard phacoemulsification as soon as possible. About four weeks after phacoemulsification a vitrectomy is performed.
Study 2: Patients with symptomduration of 3-12 months will be included in this part of the study in a prospective design.